Market Cap: $6.32B
RI
Rhythm Pharmaceuticals, Inc.
RYTM
NASDAQ (NASDAQ Global Market)USD
Market Cap: $6.32B
FDA Approval of Imcivree Marks a Milestone in Genetic Obesity Treatment Rhythm Pharmaceuticals announces a significant advancement in the management of genetically linked obesity with the FDA's recent…
Rhythm Pharmaceuticals Advances Genetic Obesity Treatment through EMANATE Trial Rhythm Pharmaceuticals conducts the EMANATE trial, a pivotal Phase 3 study that focuses on the effectiveness of setmelan…
Groundbreaking Developments in Genetic Obesity Treatment: Rhythm Pharmaceuticals and Setmelanotide Rhythm Pharmaceuticals Inc. introduces new promising findings from its Phase 3 TRANSCEND trial, which…
Rhythm Pharmaceuticals Advances Obesity Treatment with Promising Phase 3 Trial Data Rhythm Pharmaceuticals Inc. presents compelling new findings from its Phase 3 TRANSCEND trial, focusing on its obesi…
Rhythm Pharmaceuticals Advances in Rare Obesity Treatments Rhythm Pharmaceuticals announces impressive fourth-quarter results, underscoring its strategic commitment to developing innovative therapies…
Rhythm Pharmaceuticals Bolsters Growth Prospects in Q4 Earnings Report Rhythm Pharmaceuticals (NASDAQ:RYTM) has unveiled its Q4 earnings, demonstrating a substantial increase in revenue that underscor…
Rhythm Pharmaceuticals Drives Forward in Rare Genetic Disorder Treatments Rhythm Pharmaceuticals (NASDAQ:RYTM) is making notable strides in its efforts to advance therapies for rare genetic disorders,…
RBC’s Coverage Frames Rhythm as a Commercial-Stage Rare Obesity Player Commercial and Diagnostic Push for MC4R-Linked Obesity RBC Capital Markets initiates coverage of Rhythm Pharmaceuticals and frame…
Rhythm Pharmaceuticals Advances Treatment for Prader-Willi Syndrome Rhythm Pharmaceuticals Inc. announces promising preliminary results from its exploratory Phase 2 trial of setmelanotide, a treatment…
Rhythm Pharmaceuticals Sees Drop in Short Interest, Indicating Potential Shift in Investor Sentiment Rhythm Pharmaceuticals Inc, a biotechnology company specializing in treatments for rare genetic dis…
Investor Sentiment Shifts at Rhythm Pharmaceuticals Amid Declining Short Interest Rhythm Pharmaceuticals Inc. is experiencing a notable change in investor sentiment, reflected in the recent decline of…
Rhythm Pharmaceuticals Focuses on Innovation Amidst Earnings Season Rhythm Pharmaceuticals, a leader in developing therapies for rare genetic disorders, particularly in the field of metabolic diseases…
Rhythm Pharmaceuticals Prepares for Key Earnings Report Amid Growing Anticipation Rhythm Pharmaceuticals, a leader in developing innovative therapies for rare genetic disorders associated with obesity…
Rhythm Pharmaceuticals Prepares for Key Earnings Announcement Amid Focus on Rare Genetic Disorders Rhythm Pharmaceuticals is poised to release its quarterly earnings on November 4, 2025, a date that i…
Rhythm Pharmaceuticals Gears Up for Critical Earnings Report Amid Anticipation for Growth in Obesity Therapies Rhythm Pharmaceuticals is poised to release its quarterly earnings report on November 4,…
Rhythm Pharmaceuticals Faces Rising Short Interest Amid Market Scrutiny Rhythm Pharmaceuticals, a company dedicated to developing therapies for rare genetic disorders that lead to obesity, is currentl…
Rhythm Pharmaceuticals Faces Increased Short Interest Amid Market Sentiment Concerns Rhythm Pharmaceuticals, a leader in the development of treatments for rare genetic disorders of obesity, is current…
Rhythm Pharmaceuticals Faces Rising Short Interest Amidst Market Sentiment Rhythm Pharmaceuticals, a company specializing in innovative treatments for rare diseases associated with obesity, currently…
Rhythm Pharmaceuticals: Navigating Analyst Sentiment Amidst Market Complexity Rhythm Pharmaceuticals (RYTM) stands at a pivotal moment in the pharmaceutical landscape, drawing attention from a diverse…
Rhythm Pharmaceuticals: Navigating Complex Market Dynamics Rhythm Pharmaceuticals (RYTM) finds itself at a pivotal juncture, with a diverse array of insights emerging from 12 analysts over the past th…
Rhythm Pharmaceuticals Advances in Obesity Treatment with Bivamelagon Phase 2 Trial Results Rhythm Pharmaceuticals, Inc. recently announces topline results from its Phase 2 clinical trial for bivamela…
Rhythm Pharmaceuticals Advances in Obesity Treatment with Bivamelagon Trial Results Rhythm Pharmaceuticals, Inc. has recently announced the topline results from its Phase 2 clinical trial evaluating b…
Rhythm Pharmaceuticals: Navigating the Complex Landscape of Rare Disease Treatments Rhythm Pharmaceuticals, a leader in innovative treatments for rare diseases, particularly obesity and metabolic diso…
Rhythm Pharmaceuticals: Navigating the Complex Landscape of Obesity Treatments Rhythm Pharmaceuticals is currently at a pivotal moment as it focuses on its innovative approaches to treating rare disea…
Rhythm Pharmaceuticals: Navigating the Complex Landscape of Rare Disease Treatments Rhythm Pharmaceuticals is currently at a pivotal moment in its efforts to address the pressing needs of patients wit…